BusinessProtalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16, 2017By Nasdaq OMXMar 9, 2017, 12:30 PM UTC
BusinessProtalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately $24 Million of alfataliglicerase to Treat Gaucher Patients in BrazilBy Nasdaq OMXDec 14, 2016, 12:30 PM UTC
